Drug store Rite Aid Corporation (NYSE:RAD) stated on Wednesday its net loss from continuing operations of USD17.3m (USD0.02 per share) for its third fiscal quarter ended 1 December 2018.
This marks a slight improvement when compared with net loss from continuing operations of USD18.2m (USD0.02 per share) in last year's third quarter.
Revenues from continuing operations of USD5.5bn was recorded for its third fiscal quarter ended 1 December 2018, a rise over revenues from continuing operations of USD5.4bn in the prior year's third quarter.
Adjusted EBITDA from continuing operations was USD142.8m or 2.6% of revenues for the third quarter, up USD0.7m versus the Adjusted EBITDA from continuing operations of USD142.1m or 2.7% of revenues for the same period last year, an increase of
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development